HR2687

The End Kidney Deaths Act (HR2687) creates a refundable tax credit for individuals making non-directed living kidney donations. The credit is $10,000 per year for five years, totaling $50,000 per donor. This is a direct financial incentive designed to increase the number of available kidneys for transplant. The bill was introduced by Rep. Malliotakis (R-NY) and has 47 cosponsors, indicating bipartisan support and a reasonable chance of moving through committees. The money trail for this bill flows directly to individuals who donate kidneys, acting as a demand-side stimulus for organ donation. The increased supply of organs benefits the entire transplant ecosystem. Companies involved in pre-transplant evaluation, surgical procedures, post-transplant care, and related diagnostics stand to gain. This includes healthcare providers, diagnostic labs, and potentially telehealth platforms facilitating donor evaluations. The tax credit is a direct government expenditure, funded through the Internal Revenue Code, and does not involve direct contracts with specific companies. Historically, direct financial incentives for organ donation have been debated, but this specific mechanism of a refundable tax credit is novel at the federal level. While there is no direct historical precedent for a federal tax credit of this nature and scale for organ donation, similar incentives for medical procedures or health-related activities have shown to increase participation. For example, tax credits for health insurance premiums under the Affordable Care Act led to increased enrollment in health plans, benefiting insurers and healthcare providers. The exact market reaction to a similar, direct organ donation incentive is unprecedented, but increased organ availability generally benefits the healthcare system. Specific winners include companies providing diagnostic testing for transplant compatibility and post-transplant monitoring, such as LabCorp ($LH) and Quest Diagnostics ($DGX). Telehealth providers like Teladoc Health ($TDOC) and Amwell ($AMWL) could see increased utilization for initial donor screenings and follow-up consultations, streamlining the donation process. Hospitals and transplant centers, often part of larger healthcare systems, will also see increased activity. There are no clear losers from this legislation; it expands a critical healthcare resource. HR2687 has been referred to the House Ways and Means Committee and the Energy and Commerce Committee. The next step is committee hearings and potential markups. Given the bipartisan support and the nature of the incentive, the bill has a pathway to a floor vote. The timeline for passage is uncertain but could occur within the current legislative session.